Navigation Links
Neuralstem Reports Second Quarter Financial Results and Highlights
Date:8/14/2008

ase in expenses in 2008 versus 2007 is a result of increased stock-based compensation expenses, payroll and legal (both patent and corporate), including legal expense related to patent work and litigation.

Other non-operating income for the three months ended June 30, 2008 and 2007 were $10,545, and $58,058 respectively. The decrease in 2008 relates to a reduction in short term interest rates which drives income derived from our cash balance.

Net loss for the three months ended June 30, 2008 and 2007 was $2,957,672 and $1,798,911, respectively.

Results of Operations for the Six Months ending June 30, 2008 and 2007:

There were no revenues for the six month period ending June 30, 2008. In the same period in the prior year the Company had $260,324 from a licensing agreement, sales of tissue products, and the substantial completion of a discontinued National Institute of Health grant.

Research and development expenses for the six month periods ending June 30, 2008 and 2007 were $2,832,572 and $1,626,639, respectively. The increase in expenses in current period consists mainly of payroll and payroll related expenses, stock based compensation expense, research supplies and costs incurred in connection with our current effort to produce preclinical data which results in animal surgeries, manufacturing of cells, and in vitro characterization of cells which includes testing and cell quality control.

General and administrative expenses for the six month periods ending June 30, 2008 and 2007 were $2,401,877 and $1,432,167, respectively. The principal increase in expenses in the current period versus the same period last year is a result of increases in professional fees and expenses related to accountants, legal and business advisors, stock based compensation expense.

Non-operating income for the six month period ending June 30, 2008 and 2007 were $31,862, and $76,961, respectively. The largest factor influencing the reduction i
'/>"/>

SOURCE Neuralstem Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neuralstem Fills Key Product Development Position
2. Neuralstem Responds to New StemCells, Inc. Lawsuit
3. Neuralstem Sues StemCells, Inc. Over New Patent
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
6. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
7. Neuralstem Shares Accepted for Trading on Amex(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. Senetek PLC Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... at the Institute for Molecular Medicine Finland (FIMM), ... developed a novel "man and machine" decision support ... aid was described in PLOS One ... based on computer vision algorithms similar to those ... of only the diagnostically most relevant areas. Tablet ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... 21, 2014 The College of New ... college in the Mid-Hudson Region to be designated as ... accepting applications from qualified “high-technology” businesses that align with ... pleased to have been selected for the START-UP NY ... initiative to stimulate economic development in New York by ...
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... ... , ... (Vocus) February 4, 2010 -- Qteros, Inc. , a leading developer of second-generation ... announced today that Mick Sawka has joined the company as Vice President, Business Development, ...
... PARK, N.C. , Feb. 4 ... antiviral therapeutics, announced today that Gwendolyn Powell Painter , ...   , Dr. Painter has more than 20 years of ... clinical safety and pharmacovigilance, and occupational and environmental medicine.  In ...
... Mass. , Feb. 4 Interleukin Genetics, Inc. (NYSE Amex: ... at the 2010 BIO CEO & Investor Conference. The 12th Annual BIO ... the Waldorf-Astoria in New York . , Interleukin Genetics Chief Executive ... Company and discuss recent milestones at 1:00 p.m. ET in ...
Cached Biology Technology:Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 2Biofuels Technology Leader Qteros Names Mick Sawka Vice President, Business Development 3Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 2Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer 3Interleukin Genetics to Present at the 12th Annual BIO CEO Conference 2
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
(Date:8/21/2014)... a significant reduction in smog-producing toxins in past ... A new study shows that while the Greater ... the toxins that contribute to smog, the city ... air pollution., Smog, which can cause or aggravate ... bronchitis, is produced by a set of complex ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... largest study of migraines, researchers have found 5 genetic regions ... onset of migraine. This study opens new doors to understanding ... The team identified 12 genetic regions associated with migraine susceptibility. ... known to play a role in controlling brain circuitries and ...
... study shows that the predator-prey relationship can affect the ... influence on the environment may offer a new way ... climate change. The study, conducted by researchers ... comes out this week in the Proceedings of ...
... - 250 million years ago, a mammal forerunner and ... Africa, Australia and France have discovered a world first ... burrow from the Karoo Basin of South Africa. ... and fossilized after being trapped by a flash flood ...
Cached Biology News:Getting to grips with migraine 2New study shows predators affect the carbon cycle 2Oddest couple ever found 2Oddest couple ever found 3Oddest couple ever found 4
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Biology Products: